• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 144/A filed by MapLight Therapeutics Inc.

    4/15/26 4:44:33 PM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MPLT alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144/A

    144/A: Filer Information

    Filer CIK
    0001728746
    Filer CCC
    XXXXXXXX
    Previous Accession Number Of The Filing
    0001974158-26-000047
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144/A: Issuer Information

    Name of Issuer
    MapLight Therapeutics, Inc.
    SEC File Number
    001-42914
    Address of Issuer
    800 CHESAPEAKE DRIVE
    REDWOOD CITY
    CALIFORNIA
    94063
    Phone
    650-839-4360
    Name of Person for Whose Account the Securities are To Be Sold
    Lillie James Woodruff
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144/A: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Jefferies LLC
    520 Madison Avenue
    4th Floor
    New York � NY � 10022
    4896132289.924244000004/15/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144/A: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common07/30/2023Restricted Stock Unit GrantMaplight Therapeutics, Inc.Checkbox not checked320007/30/2023N/A
    Common11/09/2023Restricted Stock Unit GrantMaplight Therapeutics, Inc.Checkbox not checked143411/09/2023N/A
    Common05/02/2024Restricted Stock Unit GrantMaplight Therapeutics, Inc.Checkbox not checked614705/02/2024N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144/A: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144/A: Remarks and Signature

    Remarks
    Shares to be sold solely to satisfy tax-withholding obligations in connection w/ RSU vesting.
    Date of Notice
    04/15/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    James Lillie

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $MPLT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MPLT

    DatePrice TargetRatingAnalyst
    4/8/2026$37.00Buy
    Needham
    4/7/2026Buy
    TD Cowen
    3/19/2026$35.00Buy
    Canaccord Genuity
    11/21/2025$34.00Overweight
    Morgan Stanley
    11/21/2025$28.00Buy
    Stifel
    11/21/2025$32.00Buy
    Jefferies
    11/21/2025$30.00Outperform
    Leerink Partners
    More analyst ratings

    $MPLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pavlov George bought $441,168 worth of Voting Common Stock (25,000 units at $17.65) (SEC Form 4)

    4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)

    2/20/26 6:25:04 PM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Garnett Timothy John bought $252,678 worth of Voting Common Stock (14,124 units at $17.89) (SEC Form 4)

    4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)

    2/12/26 5:45:08 PM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Novo Holdings A/S converted options into 2,733,681 units of Voting Common Stock and bought $16,199,997 worth of Voting Common Stock (952,941 units at $17.00) (SEC Form 4)

    4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)

    10/30/25 4:31:43 PM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MPLT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026Phase 2 IRIS trial for ML-004 for autism spectrum disorder has completed enrollment, with topline results expected in the third quarter of 2026Received FDA Fast Track designation for ML-007C-MA for Alzheimer's disease psychosis; topline results from Phase 2 VISTA trial expected in the second half of 2027Expanded pipeline with a next-generation M1/M4 muscarinic agonist program, ML-055, with candidate nomination expected in 2026Ended the year with $453.1 million in cash, cash equivalents and investments, which is expected to f

    3/26/26 7:00:00 AM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MapLight Therapeutics to Participate in Upcoming Investor Conferences

    SAN FRANCISCO and BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT) today announced that members of its management team will participate in the following investor conferences: Event: Jefferies 2026 Biotech on the Beach Summit (Miami, FL)Date: Tuesday, March 10thFormat: Hosting 1x1 meetings Event: Leerink 2026 Global Healthcare Conference (Miami, FL)Date: Wednesday, March 11thFormat: Presenting and hosting 1x1 meetings Event: Stifel 2026 Virtual CNS ForumDate: Wednesday, March 18thFormat: Presenting and hosting 1x1 meetings Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the "Events & P

    3/2/26 7:00:00 AM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

    SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (NASDAQ:MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The company's Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia continues to enroll robustly, and topline results are now expected in the third quarter of 2026. The ZEPHYR study is a randomized, double-blind, placebo-controlled trial that is expected to enroll 300 hospitalized adult participants with schizophrenia experiencing acute exacerbation of psychosis. "The accelerated enrollmen

    1/9/26 7:00:00 AM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MPLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $MPLT
    SEC Filings

    View All

    $MPLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Director Malenka Robert C. sold $260,398 worth of Voting Common Stock (14,195 units at $18.34), decreasing direct ownership by 4% to 325,059 units (SEC Form 4)

    4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)

    2/24/26 6:57:12 PM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pavlov George bought $441,168 worth of Voting Common Stock (25,000 units at $17.65) (SEC Form 4)

    4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)

    2/20/26 6:25:04 PM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Malenka Robert C. sold $220,632 worth of Voting Common Stock (12,116 units at $18.21), decreasing direct ownership by 3% to 339,254 units (SEC Form 4)

    4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)

    2/18/26 7:33:37 PM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by MapLight Therapeutics Inc.

    144 - MapLight Therapeutics, Inc. (0001770069) (Subject)

    4/15/26 5:15:26 PM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 144/A filed by MapLight Therapeutics Inc.

    144/A - MapLight Therapeutics, Inc. (0001770069) (Subject)

    4/15/26 4:44:33 PM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 144/A filed by MapLight Therapeutics Inc.

    144/A - MapLight Therapeutics, Inc. (0001770069) (Subject)

    4/15/26 4:32:57 PM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham initiated coverage on MapLight Therapeutics with a new price target

    Needham initiated coverage of MapLight Therapeutics with a rating of Buy and set a new price target of $37.00

    4/8/26 8:37:23 AM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on MapLight Therapeutics

    TD Cowen initiated coverage of MapLight Therapeutics with a rating of Buy

    4/7/26 8:47:13 AM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on MapLight Therapeutics with a new price target

    Canaccord Genuity initiated coverage of MapLight Therapeutics with a rating of Buy and set a new price target of $35.00

    3/19/26 8:26:25 AM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care